Comparative effectiveness of 5-fluorouracil with and without oxaliplatin in the treatment of colorectal cancer in clinical practice

Anticancer Research

Volumn 33, Issue 3, 2013, Pages 1053-1060

  Healey, Emma ^a   Stillfried, Gillian E ^a   Eckermann, Simon ^a   Dawber, James P ^a   Clingan, Philip R ^a   Ranson, Marie ^a  

^a UNIVERSITY OF WOLLONGONG   (Australia)

Author keywords

5 fluorouracil; Capecitabine; Colorectal cancer; Comparative effectiveness research; Cost effectiveness; Oxaliplatin; Treatment effectiveness

Indexed keywords

CAPECITABINE; CETUXIMAB; FLUOROURACIL; FOLINIC ACID; IMATINIB; IRINOTECAN; MITOMYCIN; OXALIPLATIN;

AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL PRACTICE; COLORECTAL CANCER; DRUG EFFICACY; FEMALE; FOLLOW UP; HEALTH SERVICE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLORECTAL NEOPLASMS; FEMALE; FLUOROURACIL; HUMANS; MALE; NEOPLASM STAGING; ORGANOPLATINUM COMPOUNDS; PROPORTIONAL HAZARDS MODELS;

EID: 84875877497     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Malet-Martino M and Martino R: Clinical studies of three oral prodrugs of 5-fluorouracil (capecitabine, UFT, S-1): a review. Oncologist 7: 288-323, 2002.
2. Benson AB 3rd: Epidemiology, disease progression, and economic burden of colorectal cancer. J Manag Care Pharm 13: S5-18, 2007.
3. Grothey A and Sargent D: Overall survival of patients with advanced colorectal cancer correlates with availability of fluorouracil, irinotecan, and oxaliplatin regardless of whether doublet or single-agent therapy is used first line. J Clin Oncol 23: 9441-9442, 2005.
4. Andre T, Boni C, Navarro M, Tabernero J, Hickish T, Topham C, Bonetti A, Clingan P, Bridgewater J, Rivera F and de Gramont A: Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol 27: 3109-3116, 2009.
5. Andre T, Boni C, Mounedji-Boudiaf L, Navarro M, Tabernero J, Hickish T, Topham C, Zaninelli M, Clingan P, Bridgewater J, Tabah-Fisch I and de Gramont A: Oxaliplatin, Fluorouracil, and Leucovorin as Adjuvant Treatment for Colon Cancer. N Engl J Med 350: 2343-2351, 2004.
6. Borner M, Scheithauer W, Twelves C, Maroun J and Wilke H: Answering patients' needs: Oral alternatives to intravenous therapy. Oncologist 6: 12-16, 2001.
7. Ardalan B and Flores MR: A new complication of chemotherapy administered via permanent indwelling central venous catheter. Cancer 75: 2165-2168, 1995.
8. Pelusi J: Capecitabine versus 5-FU in metastatic colorectal cancer: considerations for treatment decision-making. Community Oncol 3: 19-27, 2006.
9. Twelves C, Wong A, Nowacki MP, Abt M, Burris H, 3rd, Carrato A, Cassidy J, Cervantes A, Fagerberg J, Georgoulias V, Husseini F, Jodrell D, Koralewski P, Kroning H, Maroun J, Marschner N, McKendrick J, Pawlicki M, Rosso R, Schuller J, Seitz JF, Stabuc B, Tujakowski J, Van Hazel G, Zaluski J and Scheithauer W: Capecitabine as adjuvant treatment for stage III colon cancer. N Engl J Med 352: 2696-2704, 2005.
10. Cassidy J, Twelves C, Van Cutsem E, Hoff P, Bajetta E, Boyer M, Bugat R, Burger U, Garin A, Graeven U, McKendrick J, Maroun J, Marshall J, Osterwalder B, Perez-Manga G, Rosso R, Rougier P and Schilsky RL: First-line oral capecitabine therapy in metastatic colorectal cancer: A favorable safety profile compared with intravenous 5-fluorouracil/leucovorin. Ann Oncol 13: 566-575, 2002.
11. Son HS, Lee WY, Lee WS, Yun SH and Chun HK: Compliance and effective management of the hand-foot syndrome in colon cancer patients receiving capecitabine as adjuvant chemotherapy. Yonsei Med J 50: 796-802, 2009.
12. Cassidy J, Clarke S, Diaz-Rubio E, Scheithauer W, Figer A, Wong R, Koski S, Lichinitser M, Yang TS, Rivera F, Couture F, Sirzen F and Saltz L: Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer. J Clin Oncol 26: 2006-2012, 2008.
13. Ducreux M, Bennouna J, Hebbar M, Ychou M, Lledo G, Conroy T, Adenis A, Faroux R, Rebischung C, Bergougnoux L, Kockler L and Douillard J-Y: Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/leucovorin plus oxaliplatin (FOLFOX-6) as first-line treatment for metastatic colorectal cancer. Int J Cancer 128: 682-690, 2011.
14. Rothenberg ML, Cox JV, Butts C, Navarro M, Bang YJ, Goel R, Gollins S, Siu LL, Laguerre S and Cunningham D: Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/folinic acid plus oxaliplatin (FOLFOX-4) as second-line therapy in metastatic colorectal cancer: A randomized phase III noninferiority study. Ann Oncol 19: 1720-1726, 2008.
15. Muss HB and Bynum DL: Adjuvant chemotherapy in older patients with stage III colon cancer: An Underused Lifesaving Treatment. J Clin Oncol 30: 2576-2578, 2012.
16. Schmoll HJ: Do we need oncology trials tailored for the elderly or frail? Lancet 377: 1725-1727, 2011.
17. D'Agostino RB: Estimating treatment effects using observational data. JAMA 297: 314-316, 2007.
18. Sanoff HK, Carpenter WR, Martin CF, Sargent DJ, Meyerhardt JA, Sturmer T, Fine JP, Weeks J, Niland J, Kahn KL, Schymura MJ and Schrag D: Comparative effectiveness of oxaliplatin vs. non-oxaliplatin-containing adjuvant chemotherapy for stage III colon cancer. J Natl Cancer Inst 104: 211-227, 2012.
19. Sanoff HK, Carpenter WR, Sturmer T, Goldberg RM, Martin CF, Fine JP, McCleary NJ, Meyerhardt JA, Niland J, Kahn KL, Schymura MJ and Schrag D: Effect of adjuvant chemotherapy on survival of patients with stage III colon cancer diagnosed after age 75 years. J Clin Oncol 30: 2624-2634, 2012.
20. Tracey E, Kerr T, Dobrovic A and Currow D. Cancer in New South Wales: Incidence and Mortality Report 2008. Sydney: Cancer Institute NSW; pp. 1-176, 2010.
21. NSW Health. About SESIAHS: Population. [website]: NSW Health; 2009 [updated January 15, 2008; cited June 1, 2012]; Available from: http://www.sesiahs.health.nsw.gov/about-us/population.asp.
22. Schoenfeld D: Chi-squared goodness-of-fit tests for the proportional hazards regression-model. Biometrika 67: 145-153, 1980.
23. Schoenfeld D: Partial Residuals for the Proportional Hazards Regression-Model. Biometrika 69: 239-241, 1982.
24. Sun W, Schmoll HJ, O'Connell M, Cartwright T, Twelves C, McKenna E, Saif WM, Lee LF, Yothers G and Haller DG: Comparative evaluation of capecitabine or infusional leucovorin/5-fluorouracil (LV/5-FU) with or without oxaliplatin (Ox) for stage III colon cancer (CC): A pooled analysis of individual patient data from four randomized controlled trials. J Clin Oncol 30(suppl): abstr 3525, 2012.
25. Gerard JP, Azria D, Gourgou-Bourgade S, Martel-Laffay I, Hennequin C, Etienne PL, Vendrely V, Francois E, de La Roche G, Bouche O, Mirabel X, Denis B, Mineur L, Berdah JF, Mahe MA, Becouarn Y, Dupuis O, Lledo G, Montoto-Grillot C and Conroy T: Comparison of two neoadjuvant chemoradiotherapy regimens for locally advanced rectal cancer: Results of the phase III trial ACCORD 12/0405-Prodige 2. J Clin Oncol 28: 1638-1644, 2010.
26. Glynne-Jones R and Sebag-Montefiore D: What is the impact of the addition of oxaliplatin to 5-fluorouracil-based preoperative chemoradiation in rectal cancer? Curr Colorectal Cancer Rep 7: 1-4, 2011.
27. Land SR, Kopec JA, Cecchini RS, Ganz PA, Wieand HS, Colangelo LH, Murphy K, Kuebler JP, Seay TE, Needles BM, Bearden JD, 3rd, Colman LK, Lanier KS, Pajon ER Jr., Cella D, Smith RE, O'Connell MJ, Costantino JP and Wolmark N: Neurotoxicity from oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: NSABP C-07. J Clin Oncol 25: 2205-2211, 2007.
28. Stinnett AA and Mullahy J: Net health benefits: A new framework for the analysis of uncertainty in cost-effectiveness analysis. Med Decis Making 18: 68-80, 1998.
29. Willan AR and Briggs AH. Statistical analysis of costeffectiveness data. Chichester: John Wiley & Sons, Ltd; 2006.
30. Field K, Zelenko A, Kosmider S, Court K, Ng LL, Hibbert M and Gibbs P: Dose rounding of chemotherapy in colorectal cancer: An analysis of clinician attitudes and the potential impact on treatment costs. Asia Pac J Clin Oncol 6: 203-209, 2010.
31. Eckermann S and Willan AR: Expected value of information and decision making in HTA. Health Econ 16: 195-209, 2007.
32. Willan AR and Eckermann S: Optimal Clinical Trial Design Using Value of Information Methods with Imperfect Implementation. Health Econ 19: 549-561, 2010.
33. Ruddy K, Mayer E and Partridge A: Patient adherence and persistence with oral anticancer treatment. CA Cancer J Clin 59: 56-66, 2009.
34. Winterhalder R, Hoesli P, Delmore G, Pederiva S, Bressoud A, Hermann F and von Moos R: Self-reported compliance with capecitabine: Findings from a prospective cohort analysis. Oncology 80: 29-33, 2011.
35. Dobie SA, Baldwin LM, Dominitz JA, Matthews B, Billingsley K and Barlow W: Completion of therapy by Medicare patients with stage III colon cancer. J Natl Cancer Inst 98: 610-619, 2006.
36. Cripps MC, Vincent M, Jonker D, Kerr I, Dingle B, Martin L, Mathews J, Biagi J, Knight G and Lam W: Dose reduced firstline capecitabine (XelodaTM) monotherapy in older and less fit patients with advanced colorectal cancer (ACRC). J Clin Oncol 23: (suppl), abstr 3577, 2005.
37. Feliu J, Salud A, Escudero P, Lopez-Gomez L, Bolanos M, Galan A, Vicent JM, Yubero A, Losa F, De Castro J, de Mon MA, Casado E, Gonzalez-Baron M and Grp OC: XELOX (capecitabine plus oxaliplatin) as first-line treatment for elderly patients over years of age with advanced colorectal cancer. Br J Cancer 94: 969-975, 2006.
38. Keating NL, Landrum MB, Klabunde CN, Fletcher RH, Rogers SO, Doucette WR, Tisnado D, Clauser S and Kahn KL: Adjuvant chemotherapy for stage III colon cancer: Do physicians agree about the importance of patient age and comorbidity? J Clin Oncol 26: 2532-2537, 2008.
39. Ayanian JZ, Zaslavsky AM, Fuchs CS, Guadagnoli E, Creech CM, Cress RD, O'Connor LC, West DW, Allen ME, Wolf RE and Wright WE: Use of adjuvant chemotherapy and radiation therapy for colorectal cancer in a population-based cohort. J Clin Oncol 21: 1293-1300, 2003.
40. Sargent DJ, Goldberg RM, Jacobson SD, Macdonald JS, Labianca R, Haller DG, Shepherd LE, Seitz JF and Francini G: A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients. N Engl J Med 345: 1091-1097, 2001.